Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment
Latest Information Update: 18 May 2022
Price :
$35 *
At a glance
- Drugs Hydroxycarbamide (Primary)
- Indications Central retinal vein occlusion
- Focus Therapeutic Use
- Acronyms PNPRO_HC
- 29 Nov 2016 New trial record